Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Felitan tablet is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Take a single 45 mg Fezolinetant tablet orally once daily with or without food. Take Fezolinetant with liquids and swallow whole. Do not cut, crush, or chew tablets. Administer Fezolinetant orally at about the same time each day. If a dose of Fezolinetant is missed or not taken at the usual time, administer the missed dose as soon as possible, unless there is less than 12 hours before the next scheduled dose. Return to the regular schedule the following day.Pediatric Use: The efficacy and safety of Fezolinetant in individuals less than 18 years of age have not been established.Geriatric Use: There have not been sufficient numbers of geriatric women involved in clinical trials utilizing Fezolinetant to determine whether those over 65 years of age differ from younger women in their response to Fezolinetant.
Side Effects
Common side efects of Felitan include: stomach (abdominal) pain diarrhea difculty sleeping back pain hot fashes or hot fushes Stop Felitan if you have the following signs or symptoms of liver problems: nausea vomiting itching yellowing of the eyes or skin (jaundice) pale feces dark urine pain in the right upper stomach (abdomen)
Cautions & Contraindications
Warnings & Precautions
Hepatic Transaminase Elevation and Hepatotoxicity: Elevations in serum transaminase concentrations greater than 3 times the upper limit of normal (ULN) occurred in the clinical trials. Perform hepatic laboratory tests prior to initiation of Felitan to evaluate for hepatic function and injury. Patient should not start Felitan if the concentration of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is equal to or exceeds 2 times the ULN or if the total bilirubin is elevated (for example, equal to or exceeds 2 times the ULN) for the evaluating laboratory. Patient should perform follow-up hepatic laboratory tests monthly for the frst 3 months, at 6 months, and 9 months after initiation of therapy.
Contraindications
Fezolinetant is contraindicated in women with any of the following conditions: Known cirrhosis Severe renal impairment or end-stage renal disease Concomitant use with CYP1A2 inhibitors